Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05837156
Other study ID # 950429
Secondary ID
Status Enrolling by invitation
Phase Phase 1
First received
Last updated
Start date August 2, 2023
Est. completion date December 30, 2023

Study information

Verified date July 2023
Source Sichuan Provincial People's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study uses cyclopropofol as a positive control and adopts a large sample, multicenter, randomized, single-blind, positive parallel control test design to explore the clinical application value of cyclopropofol in preventing postoperative nausea and vomiting.


Description:

Before the end of the anesthesia maintenance period/operation, it was divided into groups A, B and C according to different drug regimens. The subjects were randomly assigned to one of them in a 1:1:1 ratio to receive cyclopophenol or sevoflurane anesthesia. Each group of subjects should be roughly consistent according to the proportion of each number of PO . After screening the object, the researchers of each testing center are confirmed by the researchers of the center, log in to the random system, fill in the screening information, obtain the random number information, and distribute the corresponding research drugs according to the random number. The number of random shelters is generated through SAS software, which is used as a centralized random grouping system to import the total number of drugs. This study sets up evaluation researchers and drug management researchers. The whole experimental process turned a blind eye to not only the subjects, but also the evaluators. This study has set up evaluation investigators and administrative investigators. Administrative researchers are only involved in the random grouping, dispensing and delivery process. Other processes, including the subject's informed consent, screening, efficacy indicators and safety evaluation, and planned visits, are completed by the evaluation investigators.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 300
Est. completion date December 30, 2023
Est. primary completion date October 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. At least 2 of the 4 induced risk factors of PONV (risk factors are: history of PONV or motion sickness, habitual non-smoking, women, receiving opioid analgesia). 2. For patients with an estimated duration of anesthesia =1h and =3h (non-emergency, non-cardiothoracic surgery and non-intracranial surgery), laparoscopic surgery, gastrointestinal surgery, obstetrics and gynecology surgery, tympanoplasty, tonstonectomy, etc., are preferred. The duration of hand anesthesia was defined as the period from the beginning of anesthesia induction to the end of anesthesia maintenance 3. Male or female, age = 18 years old, ASA-PS score I to III. Exclusion Criteria: 1. There is a history of vestibular nerve disorder or dizziness or nausea and vomiting 24 hours before the operation; or receiving conventional antiemetic treatment. 2. The subjects who need to maintain ventilation after surgery or need to place the nasogastric tube in place for a period of time. 3. The subject who the researcher believes that there are any other factors that are not suitable to participate in the research.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Heptaflurane combined Cyclophenol
Heptaflurane combined Cyclophenol
Heptaflurane
Heptaflurane only
Cyclophenol
Cyclophenol only

Locations

Country Name City State
China Sichuan Provincial People's Hospital Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Mengchang Yang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of PONV within 24 hours after each group's operation. PONV incidence (%) = (number of patients with nausea and vomiting / number of PONV incidence (%) = (number of patients with nausea and vomiting / number of people in the group) × 100% Day 1
Secondary The incidence of nausea and vomiting within 48 hours after surgery in each group PONV incidence (%) = (number of patients with nausea and vomiting / number of PONV incidence (%) = (number of patients with nausea and vomiting / number of people in the group) × 100% Day 2
Secondary The average number of rescues within 24 and 48 hours after surgery in each group Severe vomiting (level 3 or above) requires rescue treatment Day 2
See also
  Status Clinical Trial Phase
Recruiting NCT05016180 - Effect of Ultrasound-guided Transversus Abdominis Plane Block After Laparoscopic Bariatric Surgery Phase 2
Withdrawn NCT00891761 - A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy Phase 3
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT05533281 - Efficacy of Three Antiemetics in Preventing Nausea and Vomiting Phase 4
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Completed NCT00293384 - Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant N/A
Completed NCT00006348 - Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Phase 3
Completed NCT00004895 - Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Phase 2
Completed NCT00003817 - Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy Phase 2
Active, not recruiting NCT06045364 - Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation Phase 1/Phase 2
Completed NCT00978185 - Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy Phase 3
Completed NCT00064272 - UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer Phase 2
Completed NCT00003213 - Drugs to Reduce the Side Effects of Chemotherapy Phase 3
Recruiting NCT05690802 - The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV N/A
Recruiting NCT06314906 - Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer Phase 3
Completed NCT00590317 - Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department Phase 2
Completed NCT03185156 - The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate Phase 4
Not yet recruiting NCT06382012 - Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Phase 2/Phase 3
Terminated NCT01275664 - Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer N/A
Completed NCT01590147 - Supportive Intervention Programs Study N/A